PGK2

PGK2 is a testis-specific glycolytic enzyme that catalyzes the first ATP-generating step of glycolysis in sperm, converting 1,3-bisphosphoglycerate to 3-phosphoglycerate with phosphorylation of ADP to ATP (PMID:19759366). It is an intronless autosomal gene that arose by RNA-mediated retroposition of the X-linked, intron-containing PGK1, and is expressed exclusively in spermatogenic cells (PMID:2823118), where its protein first appears in spermatids and persists in spermatozoa (PMID:6765230). PGK2 functionally replaces the somatic PGK1 isozyme during spermatogenesis, when X-linked PGK1 is silenced by meiotic sex chromosome inactivation and postmeiotic sex chromatin (PMID:19759366). Targeted disruption of Pgk2 eliminates sperm PGK activity and markedly reduces sperm ATP levels and motility, causing impaired male fertility without blocking spermatogenesis or altering testis histology (PMID:19759366). Testis-restricted expression is achieved through a compact promoter/enhancer in which combinatorial cis-elements act in an enhanceosome-like manner (PMID:10330089): a sequential activation program proceeds from DNA demethylation through chromatin remodeling to binding of testis-specific factors including PBX4, PREP1, CREM and SP3 at the enhancer in cells actively transcribing the gene (PMID:17875925, PMID:24000349), while upstream silencer elements repress ectopic expression in somatic tissues (PMID:10969738).

1. 1982 Medium

   Establishing when and where PGK2 protein accumulates defined it as a postmeiotic, germ-cell-restricted product rather than a constitutive isozyme.

   Evidence Immunohistochemistry with monoclonal antibodies across defined spermatogenic stages

   PMID:6765230

   Open questions at the time

   • Did not establish the enzymatic or functional requirement for the protein
   • Single lab, antibody-based detection only
2. 1987 High

   Determining the genomic origin of PGK2 showed it is a retroposon-derived, intronless duplicate of X-linked PGK1, explaining why an autosomal copy exists at all.

   Evidence Nucleotide sequence and comparative genomic analysis of human and mouse PGK genes

   PMID:2823118

   Open questions at the time

   • Did not address how testis-specific expression is achieved
   • Did not test functional role in sperm
3. 1989 High

   Localizing the information for tissue specificity showed a small 5' region is sufficient to confer testis-specific, developmentally regulated expression, defining the regulatory unit to dissect.

   Evidence Transgenic mouse CAT and luciferase reporter assays with 5' deletions

   PMID:2813402

   Open questions at the time

   • Did not identify the trans-acting factors involved
   • Did not resolve enhancer vs silencer contributions
4. 1992 Medium

   Identifying tissue-specific protein-DNA interactions distinguished a 40-bp enhancer bound by cell-restricted activities from a core promoter bound by ubiquitous Sp1 and CTF-1, framing specificity as combinatorial.

   Evidence EMSA with nuclear extracts from expressing and non-expressing tissues plus in vitro transcription

   PMID:1549104

   Open questions at the time

   • Did not molecularly identify the testis-specific factors
   • In vitro binding not confirmed in vivo
5. 1993 Medium

   Defining a positive cis element and its Ets-like binding factor (TAP-1) that competes with the PGK1 inhibitor TIN-1 linked PGK2 activation to reciprocal regulation of the two isozymes.

   Evidence Cell-free in vitro transcription, EMSA with mutant oligonucleotides, and competition assays

   PMID:8441629

   Open questions at the time

   • TAP-1 identity not molecularly cloned
   • Reciprocal regulation with PGK1 inferred from in vitro competition only
6. 1994 Medium

   Mapping the somatic silencer to a tandem two-element module explained how PGK2 is actively repressed outside germ cells.

   Evidence Deletion mapping, gel-shift, and CAT reporter assays in erythroleukemia cells

   PMID:8163199

   Open questions at the time

   • Silencer-binding factors not identified
   • Mechanism of tandem-element cooperativity unresolved
7. 2000 Medium

   In vivo deletion of an upstream negative element showed it restricts expression to germ cells, since its loss caused ectopic activation in brain and lung.

   Evidence Transgenic mice with beta-galactosidase reporters and RT-PCR/in situ hybridization

   PMID:10969738

   Open questions at the time

   • Factors mediating silencing not identified
   • Relationship to earlier mapped silencer not fully resolved
8. 1999 Medium

   Showing that single-element mutations reduced but did not abolish expression established an enhanceosome-like combinatorial logic for testis-specific transcription.

   Evidence Transgenic mice with site-directed mutations in PGK2 promoter elements driving CAT

   PMID:10330089

   Open questions at the time

   • Individual factor contributions not separated
   • Did not define the order of factor assembly
9. 2007 Medium

   Identifying PBX4/PREP1, CREM, and SP3 as enhancer-bound factors in expressing cells, with PBX4/PREP1 binding as a rate-limiting step, provided the trans-acting basis for cell-type-specific activation.

   Evidence In vivo genomic footprinting and ChIP on enriched spermatogenic cell fractions

   PMID:17875925

   Open questions at the time

   • Causal requirement of each factor not tested by loss-of-function
   • Single lab
10. 2009 High

    Knockout of Pgk2 showed it is the source of sperm PGK activity and is required for sperm ATP production, motility, and fertility, directly establishing PGK2's physiological function as the glycolytic enzyme replacing silenced PGK1.

    Evidence Targeted Pgk2 disruption in mice with enzymatic, ATP, motility, fertility, and histology readouts

    PMID:19759366

    Open questions at the time

    • Extent of acylphosphatase compensation not quantified
    • Did not resolve subcellular partitioning of glycolytic flux in the flagellum
11. 2013 Medium

    Ordering the activation program (demethylation → CAAT-factor binding → chromatin remodeling → enhancer/promoter factor binding → initiation) integrated the cis/trans findings into a sequential, stage-specific epigenetic cascade.

    Evidence ChIP for histone marks and factors, nucleosome mapping, and transgene element-disruption studies in mice

    PMID:24000349

    Open questions at the time

    • Causal hierarchy among steps largely correlative
    • Enzymes driving demethylation not identified
12. 2020 Low

    A small-molecule (esculetin) was shown to bind PGK2 directly and inhibit glycolysis, raising PGK2 as a potential pharmacological target.

    Evidence Microscale thermophoresis binding and cellular glycolysis assays in HepG2 cells

    PMID:32292350

    Open questions at the time

    • Single binding method without mutagenesis or structural validation
    • Cellular effects may reflect multi-target activity including GPD2 and GPI
    • PGK2 expression in HepG2 context not established

• How PGK2-driven ATP generation is spatially coupled to flagellar function and the extent to which alternative routes compensate for its loss remain unresolved.
• Quantitative contribution of acylphosphatase bypass not defined
• No structural model distinguishing PGK2 from PGK1 function established in the corpus
• Loss-of-function tests of individual enhancer factors lacking